Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
The original version of this Article omitted from the Author Contributions statement that ‘R.S. and J.G.R contributed equally to this work.’ This has been corrected in both the PDF and HTML versions of the Article.
Guardado en:
Autores principales: | Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b021138f6e9b4cb1925f14aab5f161ba |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Jennifer L. Caswell-Jin, et al.
Publicado: (2019) -
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
por: Sara A. Hurvitz, et al.
Publicado: (2020) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015) -
Current neoadjuvant treatment options for HER2 positive breast cancer
por: Abdel-Razeq H, et al.
Publicado: (2011) -
Impact of Intervention Measures on MRSA Clonal Type and Carriage Site Prevalence
por: Marco Cassone, et al.
Publicado: (2016)